Immuneering News

Immuneering | DEFA14A: Others

Apr 23 16:21 ET

Immuneering | DEF 14A: Definitive information statements

Apr 23 16:17 ET

Immuneering | 8-K: Current report

Mar 14 07:08 ET

Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -

Mar 1 08:06 ET

Immuneering | 8-K: Current report

Feb 2 16:17 ET

Immuneering | 8-K: Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in

Nov 9, 2023 16:05 ET

Immuneering | 8-K: Current report

Aug 3, 2023 16:04 ET

Immuneering | 8-K: Current report

Jun 15, 2023 16:15 ET

Immuneering | 8-K: Current report

Jun 14, 2023 16:08 ET

Immuneering | 8-K: Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023 16:03 ET

Immuneering | DEFA14A: Others

May 1, 2023 07:29 ET

Immuneering | DEF 14A: Definitive proxy statements

May 1, 2023 07:28 ET

Immuneering | 8-K: Current report

Apr 19, 2023 16:07 ET

Immuneering | 8-K: Current report

Apr 18, 2023 09:04 ET

Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 6, 2023 16:05 ET

Immuneering | 8-K: Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 10, 2022 09:00 ET

Immuneering: Current report (Amendment)

8-K/A | Immuneering Corp (0001790340) (Filer)

Sep 19, 2022 16:30 ET

Immuneering | S-3: Registration statement for specified transactions by certain issuers

Aug 10, 2022 16:39 ET

Immuneering | 8-K: Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 10, 2022 16:05 ET

Immuneering | 8-K: Current report

Jul 25, 2022 07:00 ET